Every batch ships straight from the lab that synthesises it — sealed, tamper-evident, and verified to >99% HPLC purity with a published batch Certificate of Analysis. View the batch Certificate of Analysis → Buying direct means you pay the lab-direct rate on every vial, with nothing stacked on top.

Order a sealed 10-vial research pack , or add a single-vial laboratory sample alongside your pack to evaluate a compound at smaller scale first. Same lab, same batch, same verified purity — scaled to whatever your research needs.

GLP1-RC-SM Batch Verification

Each released GLP1-RC-SM batch is independently analysed for chemical purity and identity, with the applicable laboratory report linked to the product batch.

New-U GLP1-RC-SM batch evidence

Catalogue identifier: GLP1-RC-SM

Batch number, vial count and declared mass per vial

RP-HPLC purity result for the released batch

Mass-spectrometry identity result for the released batch

Independent testing laboratory, report number and test date

Batch-linked Certificate of Analysis at /coa/semaglutide

Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property.

Published scientific literature

External experimental and clinical studies

Receptor pharmacology and pharmacokinetics

Protocol-defined trial endpoints and timepoints

Adverse events recorded by investigators

Registered trial records and peer-reviewed citations (DOI / PMID / NCT)

Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material.

Áreas de investigación publicadas

Los estudios publicados examinan actividad de receptores, farmacocinética y variables metabólicas, glucémicas, cardiovasculares y renales definidas por protocolo. Los resúmenes siguientes informan de lo que los investigadores midieron en esos estudios externos y no constituyen instrucciones de uso para el material de investigación suministrado aquí.

Farmacología de receptores

Agonismo de GLP-1R en localizaciones pancreáticas, gastrointestinales e hipotalámicas, caracterizado en estudios publicados de receptores.

Variables metabólicas

Cambio respecto al valor basal de la masa corporal definido por protocolo, medido en todo el programa STEP.

Variables glucémicas

HbA1c como variable definida por protocolo, medida en todo el programa de diabetes SUSTAIN.

Variables cardiovasculares y renales

Eventos cardiovasculares adversos mayores (SELECT) y eventos de enfermedad renal (FLOW), medidos en ensayos aleatorizados de resultados.

Farmacocinética

Exposición sistémica, biodisponibilidad y semivida aparente, a partir de la caracterización farmacocinética publicada.

Overview

In short: GLP1-RC-SM es un compuesto de investigación agonista de GLP-1R, denominado habitualmente “Sema” en comunidades de investigación.

Key research facts

Farmacología de receptores: actividad agonista de GLP-1R caracterizada en estudios in-vitro y de farmacología clínica publicados

Péptido de 31 aminoácidos con un 94% de homología de secuencia con GLP-1(7-37) humano nativo

Sustitución Aib8 investigada por su resistencia a DPP-IV; sustitución Arg34 investigada por una estabilidad peptídica modificada

Modificación C18 fatty-diacid/mini-PEG investigada como posible contribuyente a una exposición sistémica prolongada (semivida aparente de ~7 días)

RCT STEP-1 (NEJM 2021, PMID 33567185), brazo de 2.4 mg: los investigadores comunicaron un cambio medio de −14.9% respecto al valor basal en el peso corporal en la semana 68

These points summarise lab themes, not human outcomes.

Los trabajos publicados caracterizan la farmacología de receptores, las modificaciones estructurales y el perfil farmacocinético de esta clase de compuestos, junto con variables definidas por protocolo investigadas en programas clínicos registrados.

La verificación de lotes de New-U y la literatura externa son conjuntos de evidencia independientes: los análisis del lote establecen la identidad analítica y la pureza del material analizado; los estudios publicados describen sus propios materiales y protocolos de investigación.

Read the full scientific overview

Arquitectura molecular

Un péptido de 31 aminoácidos que comparte el 94% de su secuencia con GLP-1 humano nativo, una hormona intestinal liberada después de las comidas.

Farmacología de receptores

Los estudios de farmacología de receptores caracterizan agonismo de GLP-1R con secreción de insulin dependiente de glucosa, supresión de glucagon, retraso del vaciado gástrico y señalización de circuitos hipotalámicos del apetito. Tabla completa de la vía: Receptor Pharmacology a continuación.

Modificaciones estructurales

Se ha comunicado que GLP-1 nativo se degrada en aproximadamente dos minutos in vivo. Los trabajos estructurales publicados atribuyen la exposición sistémica prolongada de este compuesto a tres modificaciones diseñadas: una sustitución Aib8, una sustitución Arg34 y un C18 fatty diacid unido a Lys26 investigado como contribuyente a la unión a albúmina.

Farmacocinética publicada

La semivida aparente de eliminación se sitúa en aproximadamente 7 días, con alrededor del 89% de biodisponibilidad subcutánea. Perfil completo: Pharmacokinetics a continuación.

Investigación clínica

Los hallazgos publicados resumidos en esta página se refieren a estudios clínicos externos del medicamento de referencia y a sus respectivos materiales y protocolos. No establecen la seguridad, eficacia ni equivalencia clínica del material GLP1-RC-SM de New-U.

Referencias principales

Las publicaciones revisadas por pares y los registros de ensayos clínicos registrados se enumeran íntegramente, con identificadores DOI/PMID/NCT, en Source References a continuación.

Receptor Pharmacology

Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a contributor to prolonged systemic exposure.

Pathway Effect Why it matters GLP-1R (pancreatic β-cells) Agonist activity characterised in receptor pharmacology studies Glucose-dependent insulin secretion is the defining incretin property recorded in the literature GLP-1R (pancreatic α-cells) Agonist activity characterised experimentally Glucagon suppression recorded as a measured pharmacodynamic endpoint GLP-1R (gastrointestinal tract) Agonist activity characterised experimentally Delayed gastric emptying recorded as a measured pharmacodynamic endpoint GLP-1R (hypothalamus) POMC/CART activation and AgRP/NPY inhibition characterised in preclinical models The central signalling arm measured in energy-intake studies Albumin-binding modification C18 fatty diacid via a γGlu/mini-PEG spacer; >99% plasma protein binding reported Investigated as a contributor to prolonged systemic exposure (~7-day apparent half-life) Proteolytic stability Aib8 and Arg34 substitutions Structural modifications investigated for altered peptide stability against DPP-IV

Deeper dive for scientific readers

Lau et al. (J Med Chem, 2015; DOI 10.1021/acs.jmedchem.5b00726) describe three modifications relative to native GLP-1(7-37): an Aib substitution at position 8, an Arg substitution at position 34, and Lys26 acylation with a C18 fatty diacid via a γGlu/mini-PEG (AEEA) spacer. The fatty chain is reported to bind serum albumin reversibly, which the authors attribute the extended circulating exposure to. Published pharmacokinetic work reports steady-state exposure after 4–5 weeks of the protocol-defined weekly administration, with elimination via proteolytic cleavage and β-oxidation of the fatty chain and no CYP-mediated interactions. Every figure here is an observation recorded in the cited external study of the reference medicine.

Common Questions People Are Asking

¿Qué es Semaglutide en investigación científica?

Semaglutide es un agonista del receptor GLP-1 de 31 aminoácidos caracterizado en investigaciones publicadas de farmacología de receptores y clínicas. Está aprobado como medicamento en algunas jurisdicciones bajo marcas de otros fabricantes; el material suministrado aquí no es ese producto farmacéutico terminado.

¿Qué es GLP1-RC-SM?

GLP1-RC-SM es el identificador de catálogo de New-U para el material de investigación de laboratorio ofrecido mediante este perfil de investigación. No es un medicamento, un tratamiento, un producto farmacéutico genérico ni un producto terapéutico, no es equivalente a ningún producto clínico o comercial y no se ofrece para uso humano ni veterinario.

¿Qué sistemas receptores se estudian en la investigación sobre Semaglutide?

Los trabajos publicados caracterizan actividad agonista del GLP-1 receptor en cuatro contextos tisulares: células β pancreáticas (secreción de insulin dependiente de glucosa), células α pancreáticas (supresión de glucagon), tracto gastrointestinal (retraso del vaciado gástrico) y circuitos hipotalámicos (activación POMC/CART, inhibición AgRP/NPY en modelos preclínicos). Los trabajos estructurales investigan además la modificación C18 fatty-diacid de unión a albúmina y la sustitución Aib8 para modificar la estabilidad proteolítica.

¿Qué análisis analíticos acompañan a GLP1-RC-SM?

Cada lote liberado de GLP1-RC-SM se analiza en un laboratorio analítico independiente para determinar la pureza mediante normalización de área RP-HPLC y la identidad mediante espectrometría de masas, y el resultado se publica como Certificate of Analysis vinculado al lote, registrando el laboratorio, el número de informe, la pureza medida y la fecha del análisis. El análisis del lote informa sobre identidad y pureza de la muestra analizada. No establece esterilidad, estado de endotoxinas o metales pesados, equivalencia farmacéutica ni ninguna propiedad clínica.

¿Dónde puedo consultar el COA del lote actual de GLP1-RC-SM?

El certificado del lote actual, con laboratorio, número de informe, pureza medida y fecha de análisis, se publica en /coa/semaglutide junto con el historial de análisis del compuesto.

¿Qué significa una pureza HPLC >99%?

Es una cifra de pureza obtenida mediante reversed-phase high-performance liquid chromatography utilizando normalización de área: el pico objetivo representa más del 99% del área total integrada de picos del cromatograma de la muestra analizada. Es una afirmación únicamente sobre la pureza química de esa muestra y no dice nada sobre esterilidad, contenido de endotoxinas, equivalencia farmacéutica ni ninguna propiedad clínica.

¿Qué ensayos clínicos se citan en esta página?

Cinco estudios externos del medicamento de referencia: STEP-1 (Wilding et al., NEJM 2021; PMID 33567185), SELECT (Lincoff et al., NEJM 2023; PMID 37952131), FLOW (Perkovic et al., NEJM 2024; DOI 10.1056/NEJMoa2403347), SOUL (McGuire et al., NEJM 2025; DOI 10.1056/NEJMoa2501006) y el artículo estructural de Lau et al. (J Med Chem 2015). Cada resultado comunicado en esta página se atribuye a su estudio, brazo y momento temporal.

¿Cómo se distingue la investigación clínica publicada de los análisis de lotes de New-U?

Son conjuntos de evidencia separados. La investigación clínica publicada es trabajo externo sobre el producto farmacéutico terminado aprobado, realizado según los propios protocolos de esos estudios; no establece nada sobre el material suministrado aquí. Los análisis de lotes de New-U son trabajos analíticos sobre el propio lote GLP1-RC-SM, pureza RP-HPLC e identidad por espectrometría de masas, y no establecen nada clínico. Un certificado de análisis combinado con un artículo clínico externo no equivale a validación clínica de GLP1-RC-SM.

¿Es GLP1-RC-SM lo mismo que un medicamento de marca aprobado?

No. Los productos de marca aprobados de semaglutide son productos farmacéuticos terminados estériles con receta, fabricados bajo cGMP por sus titulares de autorización de comercialización. GLP1-RC-SM es material de investigación de laboratorio no aprobado suministrado como polvo liofilizado. No es equivalente, genérico ni sustituto de ningún producto aprobado.

¿En qué se diferencia Semaglutide de GLP-1 nativo?

Los trabajos estructurales publicados describen una homología de secuencia del 94% con human GLP-1(7-37) nativo además de tres modificaciones diseñadas: una sustitución Aib en la posición 8 investigada para resistencia a DPP-IV, una sustitución Arg en la posición 34 y un C18 fatty diacid unido a Lys26. Se comunica que el fatty acid se une a albúmina, a lo que la literatura atribuye la prolongación de la semivida aparente desde aproximadamente 2 minutos hasta aproximadamente 7 días.

¿En qué forma se suministra GLP1-RC-SM?

GLP1-RC-SM se suministra como polvo liofilizado en viales sellados, en paquetes de investigación sellados de 10 viales en las concentraciones indicadas, con un Certificate of Analysis vinculado al lote.

¿Cómo debe almacenarse el material de investigación de laboratorio?

Conservar el polvo liofilizado en un congelador a −20 °C. Si un protocolo de laboratorio requiere el material en solución, mantener la solución resultante refrigerada a 1–6 °C, protegida de la luz y evitar ciclos repetidos de calentamiento y enfriamiento, que pueden degradar la modificación de fatty-acid. Las condiciones de almacenamiento son únicamente información de manipulación de laboratorio.

¿Se compara directamente en investigación Semaglutide con Tirzepatide?

Un ensayo publicado, SURMOUNT-5 (NEJM 2025), fue diseñado como comparación directa y comunicó un cambio medio respecto al valor basal del peso corporal mayor en el brazo tirzepatide que en el brazo semaglutide en la semana 72 (−20.2% frente a −13.7%). Los resultados de ensayos separados de ambos compuestos no son comparaciones directas y los diseños de estudio no permiten tratarlos como tales.

Is it legal to buy Semaglutide?

In the United States, Semaglutide is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction - buyers are responsible for compliance in their own region.

Research use only - all claims made on this site are for testing and research use only.

Pharmacokinetics

Half-life Apparent elimination half-life reported at approximately 7 days (165–184 h); steady-state exposure reported after 4–5 weeks Absorption route Study protocols used subcutaneous administration (~89% reported bioavailability); a SNAC-enhanced oral tablet formulation is also described in the literature (~0.4–1% reported oral bioavailability) Bioavailability ~89% subcutaneous; 0.4–1% oral (SNAC co-formulation) reported Metabolism / clearance Proteolytic cleavage of the peptide backbone plus β-oxidation of the C18 fatty-diacid chain reported; no CYP-mediated interactions; ~3% reported excreted unchanged in urine Stability Laboratory handling — lyophilised: −20 °C. Reconstituted: 1–6 °C, protect from light; avoid repeated freeze–thaw Notes Reported volume of distribution ~12.5 L; >99% albumin-bound; clearance ~0.035 L/h. The reversible C18 fatty-diacid/albumin interaction is the protraction mechanism described in the published pharmacokinetic literature. These are observations from external studies of the reference medicine, not a handling or administration instruction for research material.

Research-Observed Effects

STEP-1 RCT (Wilding et al., NEJM 2021; PMID 33567185), overweight/obesity population, 2.4 mg arm: investigators reported a mean change from baseline in body weight of −14.9% at week 68 vs −2.4% on placebo

SELECT RCT (Lincoff et al., NEJM 2023; PMID 37952131), 17,604 participants with overweight/obesity and established cardiovascular disease without diabetes: investigators reported a 20% relative reduction in major adverse cardiovascular events

FLOW RCT (Perkovic et al., NEJM 2024): investigators reported a 24% relative reduction in major kidney-disease events in a type 2 diabetes CKD population

SOUL RCT (McGuire et al., NEJM 2025), oral (SNAC) formulation in high-risk type 2 diabetes: investigators reported a 14% relative reduction in major adverse cardiovascular events

SUSTAIN programme: investigators reported HbA1c reductions of ~1.5–1.8% as a protocol-defined endpoint, with a low reported hypoglycaemia rate attributed to glucose-dependent insulin release

Pharmacodynamic studies recorded delayed gastric emptying and reduced postprandial glucose excursions as measured endpoints

Published Research Context

Registered clinical research of the reference medicine used protocol-defined intervention arms. The STEP weight-management programme included arms from 0.25 mg up to a 2.4 mg maintenance level, with a protocol-defined step-up period of roughly 16 weeks; the SUSTAIN diabetes programme used 0.5–2.0 mg arms. Study protocols used once-weekly subcutaneous administration.

These figures are characteristics of external clinical trials of an approved medicine. They are recorded here as scientific study context and are not a protocol, schedule, starting point or instruction for any use of laboratory research material.

Adverse Events Reported in Published Clinical Research

The events below were recorded by investigators in published clinical trials of the reference medicine. They describe what was observed in those study populations under those protocols; they are not a prediction of, or guidance about, anything a reader may experience.

Common

Nausea — reported as the most frequent event, described as escalation-related and typically transient

Diarrhoea

Vomiting

Constipation

Abdominal pain and decreased appetite recorded as reported adverse events

Rare

Gallbladder events (cholelithiasis, cholecystitis)

Acute pancreatitis, reported infrequently

Injection-site reactions recorded under the study protocols

Thyroid C-cell tumours observed in rodent studies — the basis of the reference medicine’s boxed warning; human relevance reported as unconfirmed

Dose-dependent

Investigators reported gastrointestinal events scaling with arm level and during the protocol-defined step-up period, attenuating at steady state

A transient resting-heart-rate increase of a few bpm was recorded as a measured endpoint

Evidence Tier

Overall: Tier 1: Human clinical

The evidence tier describes the published literature on Semaglutide, the scientific subject, and specifically on the finished pharmaceutical studied in those trials. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material.

Tier 1 · Human clinical

STEP-1 weight-management RCT — −14.9% mean change from baseline in body weight at week 68 (NEJM 2021; PMID 33567185)

SELECT cardiovascular-outcomes RCT — 17,604 participants (NEJM 2023; PMID 37952131)

FLOW kidney-outcomes RCT (NEJM 2024); SOUL oral cardiovascular-outcomes RCT (NEJM 2025); SUSTAIN diabetes programme

Certificates, databases & peer-reviewed sources

Last reviewed: 14 August 2026 · New-U Research Compounds

Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. · 2021 · PMID: 33567185 · DOI: 10.1056/NEJMoa2032183

Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. · 2023 · PMID: 37952131 · DOI: 10.1056/NEJMoa2307563

Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Type 2 Diabetes (FLOW). N Engl J Med. · 2024 · DOI: 10.1056/NEJMoa2403347

McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. · 2025 · DOI: 10.1056/NEJMoa2501006

Lau J et al. Discovery of the Once-Weekly GLP-1 Analogue Semaglutide. J Med Chem. · 2015 · DOI: 10.1021/acs.jmedchem.5b00726

PubMed: peer-reviewed literature on Semaglutide

ClinicalTrials.gov: registered studies on Semaglutide

Semaglutide: Wikipedia (search)

WebMD: consumer health reference

BBC News: Health

CNN Health: “Peptides: what to know about the wellness trend”

Sky News: “Can peptides make America healthy again?”

Sky News: “Inside the exploding US peptides craze” (video)

Sky News Australia: “Black market peptide trade explodes as influencers fuel uptick in use”

Sky News Australia: “Backyard peptide boom sparks alarm” (video)

Sky News Australia: “Oprah reveals struggle with shame of weight-loss drugs”

Key Characteristics

31-amino-acid peptide, 94% homologous to native human GLP-1(7-37)

GLP-1R agonist activity characterised in receptor-pharmacology studies

Aib8 substitution investigated for DPP-IV resistance

C18 fatty-diacid modification reported to give >99% albumin binding

Apparent elimination half-life reported at approximately 7 days in published pharmacokinetic research

GLP1-RC-SM laboratory research material — analytically verified, >99% HPLC purity

Supplied as lyophilised powder for laboratory research; not the finished pharmaceutical studied in the cited trials

Specifications

Identificador de catálogo de New-U GLP1-RC-SM Objeto científico Semaglutide Fórmula molecular C₁₈₇H₂₉₁N₄₅O₅₉ Peso molecular 4113.58 Da Receptor caracterizado Receptor GLP-1 (GPCR clase B) Pureza (analítica) >99% por normalización de área RP-HPLC Identidad (analítica) Confirmado mediante espectrometría de masas en el lote liberado Forma Polvo liofilizado Semivida publicada Aproximadamente 7 días, 165-184 h (investigación farmacocinética externa) Conservación Liofilizado: congelador a −20 °C. Reconstituido: 1-6 °C, protegido de la luz. Uso previsto Laboratory research material. Not for human or veterinary use.

Semaglutide Research — GLP1-RC-SM Laboratory Research Material

Semaglutide is among the most extensively characterised metabolic peptides in the published literature, and the GLP-1 receptor agonist against which later compounds such as tirzepatide and the CagriSema co-formulation are benchmarked in the research record. Published structural work describes how a hormone degraded within minutes in vivo was engineered for prolonged systemic exposure by anchoring it to serum albumin via a C18 fatty-diacid modification.

Published clinical research of the reference medicine reports protocol-defined endpoints: a mean change from baseline in body weight of −14.9% at week 68 in the STEP-1 2.4 mg arm (NEJM 2021), a 20% relative reduction in major adverse cardiovascular events in SELECT (NEJM 2023), a 24% relative reduction in major kidney-disease events in FLOW (NEJM 2024), and a 14% relative reduction in major adverse cardiovascular events with the oral SNAC formulation in SOUL (NEJM 2025). Each of those figures belongs to the study, population and timepoint that produced it.

New-U Research Compounds supplies GLP1-RC-SM as lyophilised, analytically verified laboratory research material at >99% HPLC purity, with identity and purity confirmed by independent laboratories. Batch analysis reports identity and purity for the sample tested. It does not establish sterility, endotoxin or heavy-metal status, pharmaceutical equivalence, or any clinical property. Published clinical findings summarised on this page relate to the investigational materials and protocols used in those external studies. They do not establish the safety, efficacy, intended use or clinical equivalence of New-U GLP1-RC-SM research material. GLP1-RC-SM is not an approved medicine, is not the finished pharmaceutical studied in the cited trials, and is not offered for human or veterinary use.

Glucagon-like peptide-1 - Wikipedia

GLP-1 receptor agonist - Wikipedia

Customer Reviews

No customer reviews yet - be the first to share your experience.

More in Metabolic Research

Metabolic Research Retatrutide Retatrutide (LY3437943) is an investigational triple GLP-1R / GIPR / GCGR agonist evaluated in registered clinical research. GLP1-RC-RT is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Retatrutide →

Metabolic Research Tirzepatide Tirzepatide is a dual GIP / GLP-1 receptor agonist characterised in published research, with imbalanced agonism favouring GIPR. GLP1-RC-TZ is the New-U catalogue identifier for the analytically verified laboratory research material supplied here. Tirzepatide →

Metabolic Research Cagrilintide Cagrilintide (AM833), long-acting acylated amylin analogue and non-selective AMYR/CTR agonist with 8-day half-life for once-weekly obesity research. Cagrilintide →

Metabolic Research Eloralintide Eloralintide (LY3841136), a selective, long-acting amylin receptor agonist engineered for once-weekly subcutaneous obesity research, with AMY1R-preferring pharmacology. Eloralintide →

Semaglutide vs related Metabolic Research compounds

Compound Price Purity spec COA Semaglutide from $158 >99% HPLC 1 published batch Retatrutide from $210 >99% HPLC 4 published batches Tirzepatide from $168 >99% HPLC 2 published batches

Semaglutide vs Retatrutide - full comparison

Semaglutide vs Tirzepatide - full comparison

Descriptive catalog comparison for research sourcing decisions - not dosing guidance.

More on Semaglutide

Metabolic Research research compounds

Semaglutide research guide

Semaglutide pricing and packs

Research this compound

Research guide Semaglutide research guide Published experimental work characterises GLP-1R agonist activity, with an albumin-binding structural modification investigated as a… Read the guide →

Compare Compare Semaglutide and Retatrutide Semaglutide vs Retatrutide: mechanism, receptor profile and specifications side by side. Compare →

Analytical evidence View the Semaglutide COA Current batch purity and identity testing, 2025-04-30. View the COA →

Part of the Metabolic & GLP-1 research research area — explore related compounds, guides and sources.

From our community

What people say on Facebook

PRECISION. PURITY. PERFORMANCE.

Research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical & Freedom Diagnostics, with Certificates of Analysis published per released batch. Supplied strictly for laboratory research use.

Shop

All research compounds

Price list

Where to buy peptides

Research